OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Coopey on Addressing Gender Disparities in Cancer Care

March 8th 2024

Suzanne B. Coopey, MD, FACS, discusses the importance of addressing gender disparities in cancer care.

Dr Ailawadhi on Early Data for Iopofosine I 131 in Waldenström Macroglobulinemia

March 8th 2024

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

Dr Phillips on Efforts to Clarify and Refine Management Approaches in Relapsed/Refractory MCL

March 7th 2024

Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

March 7th 2024

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Dr Gopal on the Nuances of IO/TKI Selection in Advanced RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the nuances of treatment decision-making in advanced renal cell carcinoma.

Dr Gopal on the Evolution of TKI/IO Combination Approaches in RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the transition of treatment with TKIs to treatment with TKI/IO combinations for those with renal cell carcinoma.

Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant Therapy

March 7th 2024

Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.

Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting

March 7th 2024

Ajai Chari, MD, discusses the 2024 OncLive® Bridging the Gaps in Hematologic Malignancies meeting, highlighting the treatment of multiple myeloma.

Dr Wander on the ELAINE Trial Portfolio of Lasofoxifene in ER+/HER2– Breast Cancer

March 6th 2024

Seth Wander, MD, PhD, discusses the ELAINE-1, ELAINE-2, and ELAINE-3 trials in patients with ER-positive, HER2-negative metastatic breast cancer.

Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPC

March 6th 2024

Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.

Dr Park on the Sequencing of Treatment Options in Metastatic Urothelial Cancer

March 6th 2024

Chandler H. Park, MD, FACP, discusses the implications of the phase 2 TROPHY-U-01 trial in metastatic urothelial carcinoma.

Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCL

March 6th 2024

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.

Dr Roland on the Utility of Neoadjuvant Immune-Checkpoint Blockade in Liposarcoma

March 5th 2024

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Dr Phillips on Unmet Needs in Patients With Relapsed/Refractory MCL

March 5th 2024

Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.

Dr Olson on the FDA Approval of Lifileucel for Advanced Melanoma

March 5th 2024

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

Dr Gross on the Safety of Neoadjuvant Cemiplimab in Stage II/IV CSCC

March 5th 2024

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Blackwood on the Significance of Early Breast Cancer Screenings

March 5th 2024

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Dr Jagsi on the Implications of the IDEA Trial For Patients With Breast Cancer

March 4th 2024

Reshma Jagsi, MD, DPhil, discusses the implications of the IDEA trial for patients with breast cancer.

Dr Shen on the Utility of ARX517 in mCRPC

March 4th 2024

John Shen, MD, discusses the utility of ARX517 in patients with metastatic castration-resistant prostate cancer.

Dr Feldman on the Importance of the TRANSCEND CLL 004 Trial in CLL/SLL

March 4th 2024

Tatyana Feldman, MD, discusses the TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.